Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors.

Cancer science - 1 Dec 2024

Nishimura Tomomi, Velaga Ravi, Masuda Norikazu, Kawaguchi Kosuke, Kawaguchi Shuji, Takada Masahiro, Maeshima Yurina, Tanaka Sunao, Kikawa Yuichiro, Kadoya Takayuki, Bando Hiroko, Nakamura Rikiya, Yamamoto Yutaka, Ueno Takayuki, Yasojima Hiroyuki, Ishiguro Hiroshi, Morita Satoshi, Ohno Shinji, Haga Hironori, Matsuda Fumihiko, Ogawa Seishi, Toi Masakazu

Abstract excerpt

Our understanding of neoadjuvant treatment with microtubule inhibitors (MTIs) for triple negative breast cancer (TNBC) remains limited. To advance our understanding of the role of breast cancer driver genes' mutational status with pathological complete response (pCR; ypT0/isypN0) prediction and to identify distinct gene sets for MTIs like eribulin and paclitaxel, we carried out targeted genomic (n = 50) and whole...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboplatin
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Furans

Share to Ketones

Share to Neoadjuvant Therapy

Share to Paclitaxel

Share to PTEN Phosphohydrolase

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39375938
DOI: 10.1111/cas.16339
PMCID: PMC11611771

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors.PMID 39375938Read ↗

Emerging Protein Targets in Triple Negative Breast Cancer: Beyond Conventional TherapySemantic proximity Read ↗

Research advances and new challenges in overcoming triple-negative breast cancerSemantic proximity Read ↗

Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies.Semantic proximity Read ↗

Comparison of the Mutation Profiles of Triple-Negative Breast Cancers and Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers at the T2N0-1M0 StageSemantic proximity Read ↗

Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.Semantic proximity Read ↗

Identification of DDIT4 as a Potential Prognostic Marker Associated with Chemotherapy and Immunotherapy Response in Triple-Negative Breast CancerSemantic proximity Read ↗

Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer.Semantic proximity Read ↗

Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.Semantic proximity Read ↗

Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancerSemantic proximity Read ↗

An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapySemantic proximity Read ↗

An insight into the development of triple-negative breast cancer at transcriptome level based on single-cell sequencing technologySemantic proximity Read ↗

Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.